Drug dependence continues to be a persistent problem for which new treatments, both behavioral and pharmacological, are continually being developed. There is a great need to develop mechanisms by which such treatments, once shown to be efficacious, can be put into widespread clinical practice in community-based treatment programs where the largest number of drug abusers are seen. A number of barriers between researchers and clinicians, however, have made such a transition difficult, if at all possible. The recent Institute of Medicine report has challenged us to work on """"""""bridging the gap,"""""""" to address the barriers to facilitate a more functional working relationship between treatment providers and clinical researchers, who share a common goal of wanting to improve substance abuse treatment and its outcomes. NIDA has developed an action agenda to stimulate treatment providers and researchers to consider ways, from each of their perspectives, to narrow or bridge the """"""""gap."""""""" NIDA's action agenda is the development of the National Clinical Trials Network (CTN), in which researchers at Regional Research and Training Centers work in partnership with Community-based Treatment Programs both to develop areas of mutual interest for future clinical research and to test promising therapies in community settings. The present proposal seeks support to develop the Pacific Northwest (PNW) Regional Research and Training Center of the NIDA-funded Clinical Trials Network. The interdisciplinary Regional Research and Training Center, to be housed within the University of Washington Alcohol and Drug Abuse Institute (ADAI), will have as its primary focus the development, implementation, and evaluation of behavioral and pharmacological therapies, alone and in combination, targeted at drug use as delivered in the real world settings of the affiliated community-based treatment programs. It will integrate behavioral and pharmacological research as a means of informing policy, therapy development, and the evaluation process, with a goal of contributing meaningfully to the improved effectiveness of new and promising therapies developed within the larger Clinical Trials Network. The investigators have a long history of working with community based programs in research and program evaluation, collaborating on multisite clinical trials, developing and evaluating both pharmacotherapy and behavioral therapy, and conducting services research, and translating and disseminating results into information useful for clinicians and policy makers. It is this experience that we offer to the larger Clinical Trials Network.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10DA013714-03S1
Application #
6759958
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Shih, Ming L
Project Start
2001-01-10
Project End
2005-12-31
Budget Start
2003-01-01
Budget End
2003-12-31
Support Year
3
Fiscal Year
2003
Total Cost
$837,334
Indirect Cost
Name
University of Washington
Department
Psychology
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Garrett, Sharon B; Doyle, Suzanne R; Peavy, K Michelle et al. (2018) Age differences in outcomes among patients in the ""Stimulant Abuser Groups to Engage in 12-Step"" (STAGE-12) intervention. J Subst Abuse Treat 84:21-29
Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951
Barbosa-Leiker, Celestina; McPherson, Sterling; Layton, Matthew E et al. (2018) Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment. Am J Drug Alcohol Abuse 44:488-496
Miguel, André Q C; Madruga, Clarice S; Cogo-Moreira, Hugo et al. (2018) Sociodemographic Characteristics, Patterns of Crack Use, Concomitant Substance Use Disorders, and Psychiatric Symptomatology in Treatment-Seeking Crack-Dependent Individuals in Brazil. J Psychoactive Drugs 50:367-372
Lee, Joshua D; Nunes Jr, Edward V; Novo, Patricia et al. (2018) Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 391:309-318
McPherson, Sterling; Orr, Michael; Lederhos, Crystal et al. (2018) Decreases in smoking during treatment for methamphetamine-use disorders: preliminary evidence. Behav Pharmacol 29:370-374
Miguel, André Q C; Madruga, Clarice S; Simões, Viviane et al. (2018) Crack cocaine users views regarding treatment with contingency management in Brazil. Subst Abuse Treat Prev Policy 13:7
Newville, Howard; Sorensen, James L; Hatch-Maillette, Mary et al. (2018) Temporal Relationship of Sex Risk Behaviors and Substance Use Severity Among Men in Substance Use Treatment. J Sex Res 55:1056-1064
Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80
Wendt, Dennis C; Hallgren, Kevin A; Daley, Dennis C et al. (2017) Predictors and Outcomes of Twelve-Step Sponsorship of Stimulant Users: Secondary Analyses of a Multisite Randomized Clinical Trial. J Stud Alcohol Drugs 78:287-295

Showing the most recent 10 out of 126 publications